Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Galectin 14 pseudogene (LGALS17A)
- Target
- LGALS17A
- Molecular classification
- Other (Pseudogene), Galectin family (galaptin/S-lectin family; for gene lineage reference only; LGALS17A does not encode functional protein)
01
Overview
LGALS17A (galectin 14 pseudogene) is classified as a human pseudogene belonging to the galectin family, annotated as the Charcot-Leyden crystal protein pseudogene. Genomic analyses confirm its identity as non-protein-coding due to truncations, missing exons, and premature stop codons, which prevent the formation of a functional carbohydrate-recognition domain and protein product. LGALS17A is weakly transcribed in various tissues, notably including placenta, but does not generate an active galectin protein. While the galectin family is biologically important for cell–cell interactions, apoptosis, and immune regulation, LGALS17A itself should not be confused with functional galectin-14 (LGALS14) or Charcot-Leyden crystal protein (CLC/Galectin-10), which have well-defined roles in immune responses and diseases. Its characterization as a pseudogene indicates it is not a valid target for therapeutics, biomarkers, drug development, or disease modulation[3][1][2][6].
- Other names
- Charcot-Leyden crystal protein pseudogeneLGALS17AENST00000412609Galectin 14 pseudogene (human)
02
Mechanism of action
None applicable
03
Biological functions
None (LGALS17A is a pseudogene; does not produce functional protein and hence has no biological function attributed)
04
Disease associations
None directly (No established role. Charcot-Leyden crystal protein — CLC/Galectin-10 — has disease relevance, but LGALS17A pseudogene does not produce this protein)
05
Safety considerations
None (Not a therapeutic target, not an expressed protein)
06
Interacting drugs
None (No drugs interact with LGALS17A because it does not express a functional protein)
07
Biomarkers
None (Not used as biomarker)
Beyond the preview
Go deeper on Galectin 14 pseudogene (LGALS17A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Galectin 14 pseudogene (LGALS17A).